Table 1 Baseline characteristics of the trials included
Source | Patient Number (n) | Drug Type (No. of Participants) | Control Type (No. of Participants) | JIA Category | Study Type | Age (years) | Length of follow-up (months) | Risk of Bias | Disease duration TNFi (ys) | Disease duration control (ys) | Active joints with arthritis TNFi | Active joints with arthritis control | Physician’s global assessment of disease activity (0–10) TNFi | Physician’s global assessment of disease activity (0–10) control | Concomitant therapy – TNFi N (%) | Concomitant therapy - control: N (%) | GC - TNFi | GC - control | Comorbidity TNFi | Comorbidity control | Previous treatment (TNFi + control) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Burgos-Vargas et al. 2015 | 46 | Adalimumab [31] | Placebo [15] | ERA | RCT, DB | 6–18 | 12 | JADAD 4 | 2.6 ± 2.3 | 2.7 ± 2.5 | 8.4 ± 7.1 | 6.7 ± 5.3 | 5.3 ± 2.2 | 5.2 ± 20.5 | 27 (87.1) NSAID 21 (67.7) DMARD | 14 (93.3) NSAID 11 (73.3) DMARD | N = no data 0.2 mg/kg | N = no data 0.2 mg/kg | 0 | 0 | NSAID, DMARD, GC |
Horneff et al. 2015 | 38 | Etanercept [20] | Placebo [18] | ERA | RCT, DB | 6–18 | 6 | JADAD 3 | 2.4 ± 2.1 | 3.2 ± 3.5 | 5.7 ± 2.6 | 5 ± 2.6 | 5.2 ± 1.9 | 5.2 ± 1.8 | NSAID 12 (60.0) SSZ | NSAID 14 (77.7) SSZ | N = no data 0.2 mg/kg | N = no data 0.2 mg/kg | 0 | 0 | NSAID, DMARD, GC, etanercept |
Brunner et al. 2018 | 154 | Golimumab (78) | Placebo (76) | PA, OA, SOJIA, Psoriatic | RCT, DB | 2–17 | 12 | JADAD 4 | > 6 mo | > 6 mo | 14.8 ± 9.2 | 15.0 ± 10.6 | 5.5 ± 2.0 | 5.7 ± 1.8 | NSAID 78 (100) MTX | NSAID 76 (100) MTX | N = 19 0.2 mg/kg | N = 14 0.2 mg/kg | 0 | 0 | NSAID, MTX, GC Golimumab |
Wallace et al. 2012 | 85 | Etanercept [42] | Placebo [43] | PA | RCT, DB | 2–17 | 12 | JADAD 4 | 4.9 ± 0.5 mo | 5.2 ± 0.6 mo | 18.3 ± 11.0 | 25.5 ± 14.4 | 7.0 ± 1.8 | 7.1 ± 1.9 | 42 (100) MTX | 43 (100) MTX | N = 42 0.5 mg/kg/d | N = 0 | 0 | 0 | MTX, GC |
Giannini et al. 2009 | 491 | Etanercept (294) | DMARD (197) | PA, OA, SOJIA | Prospective cohort, non-randomized | 2–18 | 36 | NOS 8 | 40.7 ± 41.7 mo | 20.2 ± 30.7 mo | 6 | 6 | 4 | 4 | 249 (84.7) NSAID 294 (100.0) MTX | 180 (91.4) NSAID 197 (100.0) MTX | N = 78 | N = 36 | N = 2 Uveitis | 0 | NSAID, DMARD, GC, etanercept |
Smith et al. 2005 | 12 | Etanercept [7] | Placebo [5] | JIA | RCT, DB | 2–18 | 6 | JADAD 5 | No data | No data | No data | No data | No data | No data | 3 (42.8) MTX | 4 (80.0) MTX | N = 2 | N = 2 | N = 7 Uveitis | N = 5 Uveitis | MTX, GC |
Tynjala et al. 2011 | 40 | Infliximab [20] | DMARD [20] | PA | Prospective cohort, randomized | 4–15 | 12,5 | NOS 7 | 1.5 ± 0.3 mo | 1.8 ± 1.1 mo | 18 ± 10.0 | 18 ± 12 | 4.9 ± 1.8 | 6 ± 1.8 | NSAID 20 (100) MTX | NSAID 20 (100) MTX | N = 2 0.1 mg/kg | N = 0 | 0 | N = 2 Uveitis | No previous systemic therapy |
Ramanan et al. 2017 | 90 | Adalimumab (60) | Placebo [30] | PA, OA, Psoriatic | RCT, DB | 2–18 | 24 | JADAD 5 | 5.58 ± 3.69 | 4.81 ± 3.19 | 0 | 0 | 0.7 ± 1.4 | 0.83 ± 1.09 | 60 (100) MTX | 30 (100) MTX | N = 2 0.14 mg/kg | N = 0 | N = 60 uveitis | N = 30 uveitis | MTX, GC |
Davies et al. 2015 | 1112 | Etanercept (852) | DMARD (260) | PA, OA, ERA SOJIA, Psoriatic Unspecified | Prospective cohort, registry | 4–17 | Med. 34 | NOS 8 | 3 | 1 | 5 | 6 | 3.5 | 4.0 | 453 (53) MTX | 260 (100) MTX | N = 184 | N = 47 | N = 85 uveitis | N = 26 uveitis | MTX, GC |
Muller et al. 2017 | 62 | Etanercept [30] | DMARD [32] | PA, OA, Psoriatic | RCT, SB | 2–16 | 3 | JADAD 3 | 8.5 mo | 7.8 mo | 5.1 | 4.8 | 8.5 | 7.5 | NSAID 30 (100) MTX | NSAID 32 (100) MTX or SSZ | N = 3 | N = 0 | 0 | 0 | NSAID |